AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05757037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
Study NCT05757037 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser acupuncture
Description: a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
Study NCT06267183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV001
Description: SV001 ： single-dose
Study NCT06267183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ： single-dose
Study NCT05529368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Exercise and Tai Chi Exercise interventions
Description: Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
Study NCT05925725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: • harpagozid • boswellin = LOXACON
Description: Exercise therapy
Study NCT05925725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: • harpagozid • boswellin = LOXACON
Description: Exercise therapy
Study NCT04741607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)
Description: The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
Study NCT06135480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subcision ,PRP or saline and microneedling
Description: minimally invasive procedures
Study NCT05531682 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive several injections of Placebo
Study NCT05531682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0017
Description: Subjects will receive HB0017 in different dosing regimens
Study NCT04608630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 60 MG/ML
Description: Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
Study NCT04608630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: Patients allocated to the Zoledronic acid arm will receive Zoledronic acid 5mg in 100ml 0.9% Sodium Chloride or 5% Dextrose, administered via intravenous infusion over at least 15 minutes on Study Day 1.
Study NCT04608630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% or 5% Dextrose Intravenous
Description: Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
Study NCT04608630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% or 5% Dextrose Intravenous
Description: Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
Study NCT04608630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Injection
Description: Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
Study NCT04608630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Injection
Description: Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
Study NCT04315324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKR1C3-activated Prodrug OBI-3424
Description: Given IV
Study NCT05427045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home - exercise program
Description: Home exercise program
Study NCT04889222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00050
Description: Noninvasive pulse oximeter sensor
Study NCT04889222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET SpO2
Description: Noninvasive pulse oximeter sensor
Study NCT04977921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lab session
Description: assign students to clinical modules for study the clinical lab scope of practice
Study NCT04709354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dermoscopic examination
Description: The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
Study NCT04987268 — intervention group
Intervention type: GENETIC
Intervention: clonal hematopoiesis of indeterminate potential
Description: Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-1
Description: NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
Study NCT05325632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 pulsed DC1
Description: Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-2
Description: NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-3
Description: NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
Study NCT06361940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors or tamoxifen
Description: Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status.
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Study NCT04466566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will serve as the control
Study NCT05348122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103,Q2W
Description: TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Study NCT06235333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Disorder Screening Day screener
Description: See descriptions
Study NCT05348122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103,QW
Description: TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Study NCT04466566 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39
Description: Exendin-9,39 will block the GLP-1 receptor
Study NCT06235333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Disorder Screening Day information sheet
Description: See descriptions
Study NCT06333093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare
Description: Two (2) cold snare resections of the duodenal mucosa during an already scheduled upper gastrointestinal interventional endoscopy under deep sedation (propofol).
Study NCT06345131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non invasive blood pressure monitoring
Description: Non invasive blood pressure monitoring
Study NCT05471232 — intervention group
Intervention type: GENETIC
Intervention: Genomic sequencing and molecular diagnostic results, if any.
Description: Genomic sequencing results may be used for diagnosis and treatment of participants.
Study NCT05471232 — intervention group
Intervention type: OTHER
Intervention: EHR-Based Network Model
Description: EHR-based network will be created to predict psychiatric outcomes in youth with IDDs
Study NCT05027672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)
Description: A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
Study NCT05027672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5)
Description: A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and all other interventions as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
Study NCT06678516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: Participants are asked to abstain from any form of fasting or calorie restriction in one month of the study (which is also a pre-fasting washout for those volunteers that might be performing forms of fasting before the study) and then start with one month of intermittent fasting, with daily fasting duration from 7:30 to 18:30. Food is abstained from during fasting, only water and zero-calorie drinks like black coffee and unsweetened tea are allowed.
Study NCT06614686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U87 autologous CAR T-cell
Description: Treatment with U87 chimeric antigen receptor T-cell infusion.
Study NCT06614231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Combined With Chemotherapy
Description: Tislelizumab 200mg Q3W，Platinum-containing dual drug chemotherapy
Study NCT06614244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Description: OIT in DOPA group will be implemented as follows. Both the first micro-dose of the offending food and the subsequent micro-increments will be administered at home. Any interruptions and resumptions of OIT, due to intercurrent events (e.g. infections), will be managed via email with or without medical visit via video call. Patients will be provided with ondansetron (sublingual film) and instructions for its use. An explanatory letter will also be provided in case of need for emergency room access.
Study NCT06614244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culprit food elimination diet
Description: The Diet group consists of a population of children affected by acute persistent FPIES subjected to the traditional measure, i.e. the elimination diet of the incriminated food.
Study NCT06687460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief electrical stimulation
Description: During the nerve micro-reconstruction surgery, electrical stimulation is given to the distal end of the damaged nerve for 30 minutes.
Study NCT05325632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
Study NCT05325632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
Study NCT05325632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18
Study NCT05325632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection surgery
Description: After week 18, participants will undergo standard of care resection surgery.
Study NCT06687460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no nerve electrical stimulation
Description: only nerve microsurgical reconstruction, no nerve electrical stimulation
Study NCT06627907 — intervention group
Intervention type: OTHER
Intervention: fluid challenge
Description: The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M
Study NCT06627907 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: end-expiratory occlusion test
Description: The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes \[32, 33\]). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline 2) (T1) after one minute the EEOT is then performed by stopping the mechanical ventilation for 30 seconds (T2 - end of the EEOT test); 3) (T3) a FC of overall 6 mL/Kg of crystalloid solution is infused over 10 minutes (T4 end of the FC). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment.~The protocol is entirely intraoperative and data collections ends after FC administration. No follow-up is needed.~The mentioned timepoints T0 - T1 - T2, corresponding to intrapeortive data recording points are also the endpoints of the study. At each specific timepoint, a marker is added to the M
Study NCT04895345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study NCT05348122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,Q2W
Description: Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
Study NCT05348122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,QW
Description: Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Study NCT05348122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide,QW
Description: Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
Study NCT05392283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AERO vacuum cupping device
Description: The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
Study NCT06053372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: Wearable monitor for heart rate and arrhythmia detection
Study NCT06564740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.
Study NCT06564740 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: Oral daily dosage of 20mg.
Study NCT06114628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: Oral daily dosage of 1000mg.
Study NCT05317195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP-4
Description: NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
Study NCT04895345 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Intensity-modulated conformal radiotherapy (IMRT) is a kind of three dimensional conformal radiotherapy, which requires the dose intensity in the radiation field to be adjusted according to certain requirements.
Study NCT04159506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness, emotion didactics, interpersonal skills, experiential learning
Description: mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
Study NCT04159506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness, emotion didactics, interpersonal skills, experiential learning
Description: mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
Study NCT06243484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-070
Description: 12 weeks of TOTUM-070 supplementation with Placebo (blinded arms)
Study NCT06243484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 8 capsules per day to consume orally in two intakes
Study NCT05421871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spinal Stabilization Exercises
Description: Spinal Stabilization Exercises technique
Study NCT05421871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maitland Mobilization Along With Laser Therapy
Description: Maitland Mobilization Along With Laser Therapy technique
Study NCT04836312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soft Commitment Device
Description: Patients randomized to the commitment device arm will be asked to visit the Way to Health platform. There, they will identify a support person, a family or friend who they speak to frequently and who is invested in their health. They will then complete a series of questions intended to create implementation intentions. Specifically, they will pick a time for their fast to begin each 24-hour period and a time for their fast to end. They will also develop strategies to deal with hunger arising during a fast period. After this process, they will sign a contract pledging to adhere to the 16:8 time-restricted feeding dietary pattern, and acknowledging that their support person will receive a copy of the contract and weekly updates about their adherence to the regimen.